Status:
COMPLETED
Plasma-free Replacement in Patients With Multiple Myeloma
Lead Sponsor:
Zhongnan Hospital
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To evaluate whether the technique of no plasma exchange is suitable for the treatment, clinical efficacy, safety, and suitability of multiple myeloma patients with M protein abnormality or renal failu...
Detailed Description
Multiple myeloma (MM) is the second most common hematological tumor after non-Hodgkin's lymphoma. The tumor cells originate from plasma cells in the blood pulp and are classified as plasma cells blood...
Eligibility Criteria
Inclusion
- 1\. Clinical diagnosis of MM 2. A stable condition after routine treatment 3. Clinical diagnosis of renal insufficiency or M protein abnormalities 4．more than 18 years old 5．With liver and kidney function 6. With normal heart function; 7. Physical condition score 0-2 (ECOG score) 8. Get informed consent from the patient or family member.
Exclusion
- Allergies or obvious contraindications to any drug;
- Myocardial infarction and cardiac insufficiency
- Other malignant tumors
- TB patients and HIV positive patients 5．Other blood system diseases
- 6\. Pregnant or lactating women; 7. Not understand or follow the protocol; 8. Allergy
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2023
Estimated Enrollment :
119 Patients enrolled
Trial Details
Trial ID
NCT05251896
Start Date
January 1 2020
End Date
January 31 2023
Last Update
July 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 430071